An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. ...
Aug 31, 2022
0
115
The U.S. Food and Drug Administration has approved Roche's Tecentriq as adjuvant treatment following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer, as determined by an FDA-approved ...
Oct 18, 2021
0
3
Epithelial ovarian cancer (EOC) is the most common lethal gynecological cancer. Ovarian cancer is usually treated with platinum-based chemotherapy; however, a significant number of patients are resistant to such treatments ...
May 27, 2021
0
1
Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell ...
May 25, 2021
0
1
A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects and more ability to ...
Mar 16, 2020
0
210
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
NUS chemists have developed a novel ratiometric fluorescent probe for studying cellular activity of the clinically important anticancer drug cisplatin for next generation drug development.
Feb 19, 2019
0
6
Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress ...
Oct 22, 2018
0
1
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...
Sep 20, 2018
0
60
(HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless ...
Jun 4, 2018
0
4
